Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human amniotic epithelial cell-derived extracellular vesicles (hAEC-EVs) are a cell-free therapeutic modality being investigated for their regenerative, anti-inflammatory, and immunomodulatory properties. These vesicles are nano-sized, membrane-bound particles secreted by human amniotic epithelial cells, which are harvested from the innermost layer of the placenta. hAEC-EVs carry a complex cargo of bioactive molecules, including microRNAs (miRNAs), proteins, and lipids, that facilitate paracrine signaling to recipient cells. In the context of dry eye disease (DED), hAEC-EVs have demonstrated the ability to reduce ocular surface inflammation, promote the repair of the corneal epithelium, and restore tear film stability by suppressing oxidative stress and modulating pro-inflammatory signaling pathways. As a cell-free alternative to stem cell therapy, they offer advantages such as lower immunogenicity, easier storage, and a reduced risk of tumorigenicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human amniotic epithelial cell-derived extracellular vesicles.